[PDF][PDF] Genomic, pathway network, and immunologic features distinguishing squamous carcinomas

JD Campbell, C Yau, R Bowlby, Y Liu, K Brennan… - Cell reports, 2018 - cell.com
JD Campbell, C Yau, R Bowlby, Y Liu, K Brennan, H Fan, AM Taylor, C Wang, V Walter…
Cell reports, 2018cell.com
Summary This integrated, multiplatform PanCancer Atlas study co-mapped and identified
distinguishing molecular features of squamous cell carcinomas (SCCs) from five sites
associated with smoking and/or human papillomavirus (HPV). SCCs harbor 3q, 5p, and
other recurrent chromosomal copy-number alterations (CNAs), DNA mutations, and/or
aberrant methylation of genes and microRNAs, which are correlated with the expression of
multi-gene programs linked to squamous cell stemness, epithelial-to-mesenchymal …
Summary
This integrated, multiplatform PanCancer Atlas study co-mapped and identified distinguishing molecular features of squamous cell carcinomas (SCCs) from five sites associated with smoking and/or human papillomavirus (HPV). SCCs harbor 3q, 5p, and other recurrent chromosomal copy-number alterations (CNAs), DNA mutations, and/or aberrant methylation of genes and microRNAs, which are correlated with the expression of multi-gene programs linked to squamous cell stemness, epithelial-to-mesenchymal differentiation, growth, genomic integrity, oxidative damage, death, and inflammation. Low-CNA SCCs tended to be HPV(+) and display hypermethylation with repression of TET1 demethylase and FANCF, previously linked to predisposition to SCC, or harbor mutations affecting CASP8, RAS-MAPK pathways, chromatin modifiers, and immunoregulatory molecules. We uncovered hypomethylation of the alternative promoter that drives expression of the ΔNp63 oncogene and embedded miR944. Co-expression of immune checkpoint, T-regulatory, and Myeloid suppressor cells signatures may explain reduced efficacy of immune therapy. These findings support possibilities for molecular classification and therapeutic approaches.
cell.com